Bioavailability and metabolic effects in humans of n-3 polyunsaturated fatty acids and conjugated linoleic acid after consumption of naturally enriched cow milk

Bioavailability and metabolic effects in humans of n-3 polyunsaturated fatty acids and conjugated linoleic acid after consumption of naturally enriched cow milk: a randomised double blind parallel group trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN16004121

Enrollment

Registered

2010-02-26

Start date

2009-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutrition Nutritional, Metabolic, Endocrine Nutrition

Interventions

Experimental group: 500 ml/day of test milk Control group: 500 ml/day of regular milk The methodology is the same for participants in the two arms of the study, except for the milk product given (mil

safety haematological and biochemical analytes by standard clinical laboratory automated methods

and plasma fatty acids by gas chromatography.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Healthy men and women volunteers 2. Aged between 18 and 50 years 3. Overweight (body mass index [BMI] between 25.0 and 29.9 kg/m^2) 4. Sign an informed consent

Exclusion criteria

Exclusion criteria: 1. Subjects with a prior history of cardiovascular disease, cancer, any severe chronic disease, psychiatric condition, alcoholism or drug abuse 2. Milk intolerance 3. Intake of fish oil capsules or fish oil enriched foods in the prior 3 months 4. Consumption of fatty fish more than once per week 5. BMI outside of pre-specified range

Design outcomes

Primary

Measure	Time frame
Determination of plasma fatty acid content at baseline and after 6 weeks of consumption of experimental and control milks	—

Secondary

Measure	Time frame
1. Medical record, including anthropometric measurements (height, weight and waist circumference) and blood pressure at baseline and end of treatment 2. Food, energy and nutrient intake assessed by 7-day food records prior to entry and on the last week of intervention 3. Blood chemistry, with safety profile (complete blood count, fasting blood glucose, creatinine, uric acid, alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], and total protein) and lipid profiles (total cholesterol, high density lipoprotein [HDL] cholesterol, low density lipopotein [LDL] cholesterol and triglycerides) at baseline and the end of treatment	—

Measure

Time frame

1. Medical record, including anthropometric measurements (height, weight and waist circumference) and blood pressure at baseline and end of treatment 2. Food, energy and nutrient intake assessed by 7-day food records prior to entry and on the last week of intervention 3. Blood chemistry, with safety profile (complete blood count, fasting blood glucose, creatinine, uric acid, alanine aminotransferase [ALT], aspartate aminotransferase [AST], gamma-glutamyl transferase [GGT], and total protein) and lipid profiles (total cholesterol, high density lipoprotein [HDL] cholesterol, low density lipopotein [LDL] cholesterol and triglycerides) at baseline and the end of treatment

—

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026